skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for “Second Generation” Therapeutic Application

Journal Article · · Journal of Pharmaceutical Sciences
 [1];  [2];  [1];  [2];  [3];  [3];  [1];  [1];  [1]
  1. Florida State Univ., Tallahassee, FL (United States)
  2. Univ. of Kansas, Lawrence, KS (United States)
  3. Washington Univ. School of Medicine, St. Louis, MO (United States)

Human fibroblast growth factor-1 (FGF-1) has broad therapeutic potential in regenerative medicine but has undesirable biophysical properties of low thermostability and 3 buried cysteine (Cys) residues (at positions 16, 83, and 117) that interact to promote irreversible protein unfolding under oxidizing conditions. Mutational substitution of such Cys residues eliminates reactive buried thiols but cannot be accomplished simultaneously at all 3 positions without also introducing further substantial instability. The mutational introduction of a novel Cys residue (Ala66Cys) that forms a stabilizing disulfide bond (i.e., cystine) with one of the extant Cys residues (Cys83) effectively eliminates one Cys while increasing overall stability. This increase in stability offsets the associated instability of remaining Cys substitution mutations and permits production of a Cys-free form of FGF-1 (Cys16Ser/Ala66Cys/Cys117Ala) with only minor overall instability. The addition of a further stabilizing mutation (Pro134Ala) creates a Cys-free FGF-1 mutant with essentially wild-type biophysical properties. The elimination of buried free thiols in FGF-1 can substantially increase the protein half-life in cell culture. In this work, we show that the effective cell survival/mitogenic functional activity of a fully Cys-free form is also substantially increased and is equivalent to wild-type FGF-1 formulated in the presence of heparin sulfate as a stabilizing agent. The results identify this Cys-free FGF-1 mutant as an advantageous “second generation” form of FGF-1 for therapeutic application.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
Trefoil Therapeutics, LLC; Florida State University; National Institutes of Health (NIH)
Grant/Contract Number:
HL105732
OSTI ID:
1247356
Journal Information:
Journal of Pharmaceutical Sciences, Vol. 105, Issue 4; ISSN 0022-3549
Publisher:
ElsevierCopyright Statement
Country of Publication:
United States
Language:
ENGLISH
Citation Metrics:
Cited by: 12 works
Citation information provided by
Web of Science

References (42)

Structural and energetic consequences of disruptive mutations in a protein core journal May 1992
Mutation Choice to Eliminate Buried Free Cysteines in Protein Therapeutics journal February 2015
Disulfide Bonds are Neither Required, Present, Nor Compatible with Full Activity of Human Recombinant Acidic Fibroblast Growth Factor journal January 1990
Engineered Disulfide Bonds in Staphylococcal Nuclease:  Effects on the Stability and Conformation of the Folded Protein journal January 1996
Redesigning symmetry-related “mini-core” regions of FGF-1 to increase primary structure symmetry: Thermodynamic and functional consequences of structural symmetry journal September 2005
X-ray and Thermodynamic Studies of Staphylococcal Nuclease Variants I92E and I92K: Insights into Polarity of the Protein Interior journal August 2004
Thermodynamic Characterization of Mutants of Human Fibroblast Growth Factor 1 with an Increased Physiological Half-Life journal June 2000
Acidic Fibroblast Growth Factor Accelerates the Healing of Acetic-Acid-lnduced Gastric Ulcers in Rats journal January 1992
Reversible Thermal Denaturation of Human FGF-1 Induced by Low Concentrations of Guanidine Hydrochloride journal July 1999
The structure of human acidic fibroblast growth factor and its interaction with heparin journal August 1991
Accommodation of a highly symmetric core within a symmetric protein superfold journal December 2003
Structural Basis of Conserved Cysteine in the Fibroblast Growth Factor Family: Evidence for a Vestigial Half-Cystine journal October 2009
Coot model-building tools for molecular graphics journal November 2004
The Interaction between Thermodynamic Stability and Buried Free Cysteines in Regulating the Functional Half-Life of Fibroblast Growth Factor-1 journal October 2009
Stability and rigidity/flexibility—Two sides of the same coin? journal May 2013
Improved data visualization techniques for analyzing macromolecule structural changes: Techniques for Analyzing Macromolecule Structure journal September 2012
Plasticity in Interactions of Fibroblast Growth Factor 1 (FGF1) N Terminus with FGF Receptors Underlies Promiscuity of FGF1 journal November 2011
The role of cysteine oxidation in the thermal inactivation of T4 lysozyme journal January 1987
Structure and stability effects of mutations designed to increase the primary sequence symmetry within the core region of a β-trefoil journal December 2001
The use of fluorescence methods to monitor unfolding transitions in proteins journal February 1994
Receptor Specificity of the Fibroblast Growth Factor Family journal June 1996
Acidic Fibroblast Growth Factor Accelerates Dermal Wound Healing in Diabetic Mice journal May 1995
A Polypeptide “Building Block” for the β-Trefoil Fold Identified by “Top-Down Symmetric Deconstruction” journal April 2011
Acidic Fibroblast Growth Factor Accelerates Dermal Wound Healing journal January 1992
AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures journal April 2015
The Fibroblast Growth Factor signaling pathway journal March 2015
Rigidity versus flexibility: the dilemma of understanding protein thermal stability journal July 2015
Heparin-Induced Thrombocytopenia: An Update journal March 2012
Strong hydrophobic nature of cysteine residues in proteins journal September 1999
Participation of cysteine and cystine in inactivation of tyrosine aminotransferase in rat liver homogenates journal November 1978
Free R value: a novel statistical quantity for assessing the accuracy of crystal structures journal January 1992
Spackling the Crack: Stabilizing Human Fibroblast Growth Factor-1 by Targeting the N and C terminus β-Strand Interactions journal August 2007
The interpretation of protein structures: Total volume, group volume distributions and packing density journal January 1974
Hydrophobic packing in T4 lysozyme probed by cavity-filling mutants. journal November 1989
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997
Automated Structure Solution with the PHENIX Suite book January 2008
X-ray Crystal Structure of Human Acidic Fibroblast Growth Factor , journal January 1996
Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth Factors: First Clinical Results of a New Treatment of Coronary Heart Disease journal February 1998
Conformational stability and activity of ribonuclease T1 with zero, one, and two intact disulfide bonds. journal August 1988
Contribution of conformational stability and reversibility of unfolding to the increased thermostability of human and bovine superoxide dismutase mutated at free cysteines. journal December 1990
Regeneration of Active Enzyme from the Mixed Disulfide of Egg White Lysozyme and Cystine journal June 1965
Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor. journal March 1991

Cited By (2)

Aggrescan3D (A3D) 2.0: prediction and engineering of protein solubility journal May 2019
Unraveling the Connection between Fibroblast Growth Factor and Bone Morphogenetic Protein Signaling journal October 2018